Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
NCT05309629Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in small cell lung cancer (SCLC), sponsored by Qilu Pharmaceutical. Started Apr 2022; status: completed.
02
Drugs
QL1706
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05309629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309629.